Adjust Font Sizing:

Now Accepting Applications to be a 2019-2020 Youth Ambassador

Narcolepsy Network (NN) is now accepting applications for the Youth Ambassador Program (YA). This is a national program designed to train promising young members of NN to […]

Clinical Trial for the Treatment of Excessive Daytime Sleepiness and Cataplexy

Axsome Therapeutics is pleased to announce a new clinical trial of an investigational oral medication, AXS-12, for the treatment of excessive daytime sleepiness and cataplexy associated with […]

New Membership Levels and Benefits

We are making some changes to our membership program in 2019, with the introduction of three new levels of membership (including a much-requested family membership). In this […]

Upcoming Support Group Meetings

Having the support of other people with narcolepsy is an important part of living well with narcolepsy. One of the best ways to get this support is […]

We Are Running the 2019 TCS New York City Marathon

We are excited to announce that Narcolepsy Network will once again be running the TCS New York City Marathon this fall as an Official Charity Partner! Last […]

Narcolepsy Advocates Went to Washington for Rare Disease Week

In year’s past, Narcolepsy Network was able to send our Executive Director or a board member or two to Rare Disease Week on Capitol Hill. This year, […]

Harmony Biosciences Announces File Acceptance Of Its New Drug Application For Pitolisant

In early 2018, NN put together a panel of people with narcolepsy (PWNs), doctors, and advocates to petition the FDA to grant fast-track status to new medications. […]

Year in Review

2018 was a busy year! We had the honor of speaking to representatives at the Food and Drug Administration (FDA) to encourage the development of new medications. […]

New Membership Levels and Benefits

We are making some changes to our membership program in 2019, with the introduction of three new levels of membership (including a much-requested family membership). In this […]

FDA Approves Xyrem in Pediatric Patients with Narcolepsy

The US Food and Drug Administration (FDA) approved Xyrem (sodium oxybate) for the treatment of cataplexy and excessive daytime sleepiness (EDS) in pediatric patients ages 7-17 with narcolepsy. Read […]

Do NOT follow this link or you will be banned from the site!